人乳头瘤病毒18型L1蛋白在昆虫杆状病毒系统中的表达

目的:利用昆虫杆状病毒系统表达人乳头瘤病毒18型(HPV18)L1蛋白。方法:将L1基因与p Fast Bac1(p FB1)载体连接,构建转移载体p FB1-L1,转化含Bacmid的大肠杆菌DH10Bac感受态细胞,获得穿梭质粒r Bacmid-L1;r Bacmid-L1转染Sf9细胞,获得重组病毒r Bac-L1;PCR法检测重组杆状病毒基因组L1基因,间接免疫荧光法和Western印迹检测L1蛋白的表达。结果:穿梭质粒r Bacmid-L1经PCR鉴定构建正确;感染r Bac-L1的Sf9细胞经PCR扩增可见1629 bp的特异性条带,间接免疫荧光检测可见绿色荧光,Western印迹鉴定与小鼠抗L1单克隆抗体发生特异性反应,在相对分子质量约60 000处可见特异性条带。结论:利用昆虫杆状病毒表达系统表达了HPV18 L1蛋白。     

密码子优化型HPV16L1基因在两种昆虫细胞中的表达

目的:提高16型人乳头瘤病毒（HPV16）L1基因在杆状病毒昆虫细胞中的表达水平,为研制预防性HPV疫苗奠定基础。方法:根据昆虫细胞密码子偏性对野生型HPV16L1基因进行改造,利用Bac-to-Bac表达系统获得重组杆状病毒,感染昆虫细胞Sf9和High Five。Western blot鉴定表达产物;电镜下观察病毒样颗粒形成。利用ELISA法评价HPV16L1基因的优化效果,探讨L1蛋白表达的最佳条件。结果:在相对分子质量56kDa处出现HPV16L1的特异性条带;电镜下可见病毒样颗粒在昆虫细胞的核内形成;优化型HPV16L1基因的表达水平显著高于野生型。High Five细胞表达的最佳条件为MOI=10,表达时相72h,其L1蛋白表达量至少比Sf9细胞高3倍。结论:密码子优化技术确实能够促进HPV16L1蛋白的高效表达,而High Five细胞表现出的显著优势尤其值得关注。     

截短型人乳头瘤病毒58型L1蛋白的表达及其体外生物活性研究

利用PCR技术克隆截短型HPV58 L1基因并重组入杆状病毒表达系统穿梭质粒pFastBac-Htb,通过转座反应,将目的基因片段重组入杆状病毒基因组,分离重组的Bacmid DNA, 并转染Sf-9昆虫细胞,收集被转染的Sf-9细胞,提取细胞蛋白,SDS-PAGE检测可见在大约58Kda处出现一新生蛋白条带,Western blot 证实为HPV58L1蛋白。用ProBondTM纯化系统纯化所表达的蛋白。小鼠红细胞凝集试验证实纯化的蛋白可介导小鼠红细胞凝集,透射电镜观察证实纯化蛋白可自组装成VLP。结果表明昆虫杆状病毒表达系统可高效表达截短型HPV58L1蛋白,纯化后的截短型HPV58L1蛋白在体外可自组装VLP,并具有介导小鼠红细胞凝集的生物学活性。     

分子伴侣促进截短型人乳头瘤病毒58亚型L1蛋白在大肠杆菌中的可溶性表达

目的:采用分子伴侣pTf16共表达的形式促进截短型人乳头瘤病毒(HPV)58亚型L1蛋白在大肠杆菌中的可溶性表达。方法:将重组表达质粒pGEX-6P-HPV58-L1转入含有分子伴侣pTf16的大肠杆菌BL21感受态细胞中,在2.0 mg/mL L-阿拉伯糖诱导表达20 min之后加入1.0 mmol/L的IPTG,18℃诱导表达24 h,使目的蛋白与伴侣蛋白共表达;重组蛋白经GST亲和纯化后去除GST标签免疫昆明鼠,ELISA检测免疫血清效价。结果:分子伴侣pTf16能显著提高目的蛋白的可溶性表达,经纯化及去除GST标签,用SDS-PAGE与Western印迹检测,约在相对分子质量50×103处出现特异性反应条带,该条带与截短型HPV58 L1蛋白预期大小相符,免疫动物后经ELISA检测小鼠血清的抗体效价为1∶6400。结论:获得了截短型HPV58 L1蛋白,动物免疫试验证实该蛋白具有较好的免疫原性,为进一步研制HPV58预防型疫苗奠定了基础。     

膜蛋白KCNN1在昆虫细胞Sf9中的表达与纯化

目的:利用昆虫细胞表达系统真核表达并纯化小电导钙激活钾离子通道蛋白1(KCNN1)。方法:以基因重组方法构建杆状病毒穿梭质粒reBacmid-KCNN1,将其转染至杆状病毒/Sf9细胞表达系统表达目的蛋白,并用Western印迹鉴定KCNN1的表达水平;用Ni-IDA-Sepharose CL-6B亲和层析柱纯化裂解细胞上清中的KCNN1,并用Western印迹鉴定纯化结果。结果:KCNN1在Sf9细胞中高效表达,通过亲和层析获得了纯化的KCNN1。结论:膜蛋白KCCN1在昆虫细胞Sf9中的表达与纯化,为深入研究其分子生物学功能提供了材料,也为全长膜蛋白的体外表达提供了一套可借鉴的实验方法。     

16型人乳头瘤病毒衣壳蛋白在真核细胞中的表达

为了构建HPV16型晚期蛋白重组杆状病毒,并使其在昆虫细胞中获得高效表达.首先构建2株重组杆状病毒转移质粒,分别携带人乳头瘤病毒晚期基因L1及L1和L2,再用线性化的杆状病毒DNA与该重组杆状病毒转移质粒共转染sf9昆虫细胞进行同源重组,获得2株重组杆状病毒.经鉴定该重组病毒中有目的基因存在且可表达所编码的L1或L2晚期蛋白.结果表明HPV16型晚期蛋白在昆虫细胞中获得成功表达,为HPV16型预防性基因工程亚单位疫苗的研制和诊断试剂的研究开发奠定了基础.     

srhM-CSFR在昆虫细胞中的表达及其配基结合活性分析

从人胎盘中提取总 RNA,利用 RT- PCR技术扩增出巨噬细胞集落刺激因子受体 ( M-CSFR)胞外区的、具有全部配基结合活性区域的前三个免疫球样蛋白结构域的 DNA,将其克隆到杆状病毒载体 pbluebac4.5中 ,与杆状病毒 DNA一同转导昆虫细胞 Sf9.经过 2轮筛选 ,获得了纯化的重组病毒 ,再用重组病毒感染昆虫细胞 ,Western印迹检测证明 srh M- CSFR得到了表达 ,它是分泌到上清液中的糖基化蛋白 .Western印迹分析了不同时间点的 srh M- CSFR表达情况 ,结果表明 srh M- CSFR的表达在 96～ 1 2 0 h时达到最大 .srh M- CSFR的产量约为 1 mg/L,EIA法进行配基结合活性分析表明 ,srh M- CSFR与 M- CSF结合的解离常数为 5nmol/L.     

HPV16L1VLP纯化、鉴定及血凝抑制实验方法的建立

摘要通过昆虫细胞-杆状病毒表达系统表达HPV16L1 VLP,纯化鉴定后利用其建立血凝抑制实验,检测HPV16L1单克隆抗体的血凝抑制活性。利用重组杆状病毒感染悬浮培养的昆虫细胞表达HPV16L1蛋白,大量获得VLP;优化扩增蛋白的条件并用SDS-PAGE分析鉴定;经氯化铯密度梯度离心法纯化VLP;利用所得VLP建立血凝抑制试验,鉴定制备的HPV16L1单克隆抗体的血凝抑制活性。优化蛋白表达条件结果显示,当重组杆状病毒感染细胞的MOI=10时目的蛋白表达量最大;按此滴度感染悬浮培养的昆虫细胞,收获、纯化VLP并鉴定其特异性;利用所得VLP建立了血凝抑制实验,鉴定HPV16L1单克隆抗体的血凝抑制效价为1∶16。建立的血凝实验,可用于鉴定和检测HPV16L1相关抗体,为HPV诊断试剂的开发提供实验基础。     

重组人可溶性PDGFRβ/Fc在昆虫细胞Sf9中的表达

【目的】利用昆虫细胞Bac-to-Bac杆状病毒表达系统表达血小板源性生长因子受体β (PDGFRβ)链膜外区与人IgG Fc片段的可溶性受体融合蛋白sPDGFRβ/Fc,并检测重组蛋白的特异性和生物活性。【方法】采用Bac-to-Bac系统,构建重组转移质粒pFastbac-sPDGFRβ/Fc,转化到含穿梭载体Bacmid的感受态细胞DH10Bac中,使目的基因与杆状病毒基因组DNA发生位点特异性重组,获得重组病毒DNA,将其通过脂质体转染昆虫细胞Sf9获得重组病毒。将该重组病毒感染Sf9无血清细胞系,在Sf9细胞中表达sPDGFRβ/Fc,对表达产物进行Western blotting检测和Protein A亲合层析纯化,并进一步通过MTT法检测获得的重组蛋白生物学活性。【结果】重组病毒感染Sf9细胞后,经Western blotting分析,能检测到一条分子量约为97 kDa的特异性条带,与目的蛋白大小相符。通过Protein A亲和层析,获得了纯度达75％以上,表达量为1 μg/mL细胞培养上清的重组融合蛋白,MTT结果显示该重组融合蛋白sPDGFRβ/Fc具有抑制PDGF刺激的Balb/c 3T3细胞增殖的能力。【结论】具有生物活性的重组可溶性受体融合蛋白sPDGFRβ/Fc可在昆虫细胞中成功地得到表达。     

甲型H1N1流感病毒HA基因在昆虫细胞中的截短表达

目的:利用Bac-to-Bac Baculovirus Expression System表达重组HA蛋白,Western blot及IFA方法鉴定其表达。方法:采用PCR方法扩增A/California/04/2009(H1N1)HA基因,将其克隆到pFastBacHT A载体上,重组质粒pFastBacHT-HA经双酶切及测序鉴定正确后,转化阳性重组载体进入E.coli DH10Bac感受态细胞中,通过Bluo-gal蓝白斑筛选、PCR鉴定获得重组转座子rBacmid-HA。从重组转座子中提取rBacmid-HA质粒DNA转染sf 9昆虫细胞,制备重组杆状病毒。重组杆状病毒感染sf 9细胞表达重组蛋白,Western blot及IFA鉴定重组蛋白表达情况。结论:成功构建了甲型H1N1流感病毒HA基因的昆虫杆状病毒表达载体,该表达载体转染昆虫细胞后制备的重组杆状病毒病毒滴度较高,重组杆状病毒表达的重组蛋白经Western blot 及IFA 鉴定后具有良好的免疫反应原性。     

人乳头瘤病毒16型E6基因的T—A克隆及在真核细胞中的表达

由于ＨＰＶ１６Ｅ６蛋白能诱导机体保护性免疫反应,可作为基因治疗的靶抗原。用杆状病毒昆虫细胞表达系统制备了ＨＰＶ１６Ｅ６基因工程蛋白,拟用于宫颈癌细胞系小鼠模型抗癌的免疫治疗。用ＰＣＲ技术从ＨＰＶ１６基因组中扩增获得转化基因Ｅ６的完整ＯＲＦ,按ＴＡ策略将其克隆到自行制备的杆状病毒转移载体ｐＶＬ１３９３Ｔ尾载体中,置于杆状病毒ＡｃＭＮＰＶＰｏｌｈ晚期启动子控制之下,用此重组转移质粒ｐＶＬ１３９３Ｅ６与杆状病毒ＤＮＡ共转染昆虫细胞Ｓｆ９,经噬斑筛选获得带有编码Ｅ６蛋白基因的重组杆状病毒株,并在昆虫细胞Ｓｆ９中表达为非融合性Ｅ６蛋白。ＳＤＳＰＡＧＥ电泳分析其分子量约为１８ｋＤ,免疫印迹实验表明,此重组蛋白能被兔抗ＨＰＶ１６Ｅ６抗体所识别。     

High-level expression of biologically active human prolactin from recombinant baculovirus in insect cells

We examined the feasibility of high-level production of recombinant human prolactin, a multifunctional protein hormone, in insect cells using a baculovirus expression system. The human prolactin cDNA with and without the secretory signal sequence was cloned into pFastBac1 baculovirus vector under the control of polyhedrin promoter. Prolactin was produced upon infection of either Sf9 or High-Five cells with the recombinant baculovirus containing the human prolactin cDNA. The production of recombinant prolactin varied from 20 to 40 mg/L of monolayer culture, depending on the cell types. The prolactin polypeptide with its own secretory signal was secreted into the medium. N-terminal amino acid sequence analysis of the recombinant polypeptide purified from the culture medium indicated that the protein was processed similar to human pituitary prolactin. Carbohydrate analysis of the purified protein indicated that a fraction of the recombinant prolactin made in insect cells appeared to be glycosylated. Also, both secreted and nonsecreted forms of the recombinant prolactin in insect cells were biologically equivalent to the native human prolactin (pituitary derived) in the Nb2 lymphoma cell proliferation assay.     

Immunogenicity of a Trivalent Human Papillomavirus L1 DNA-Encapsidated,Non-Replicable Baculovirus Nanovaccine

Previously, we developed a non-replicating recombinant baculovirus coated with human endogenous retrovirus envelope protein (AcHERV) for enhanced cellular delivery of human papillomavirus (HPV) 16L1 DNA. Here, we report the immunogenicity of an AcHERV-based multivalent HPV nanovaccine in which the L1 segments of HPV 16, 18, and 58 genes were inserted into a single baculovirus genome of AcHERV. To test whether gene expression levels were affected by the order of HPV L1 gene insertion, we compared the efficacy of bivalent AcHERV vaccines with the HPV 16L1 gene inserted ahead of the 18L1 gene (AcHERV-HP16/18L1) with that of AcHERV with the HPV 18L1 gene inserted ahead of the 16L1 gene (AcHERV-HP18/16L1). Regardless of the order, the bivalent AcHERV DNA vaccines retained the immunogenicity of monovalent AcHERV-HP16L1 and AcHERV-HP18L1 DNA vaccines. Moreover, the immunogenicity of bivalent AcHERV-HP16/18L1 was not significantly different from that of AcHERV-HP18/16L1. In challenge tests, both bivalent vaccines provided complete protection against HPV 16 and 18 pseudotype viruses. Extending these results, we found that a trivalent AcHERV nanovaccine encoding HPV 16L1, 18L1, and 58L1 genes (AcHERV-HP16/18/58L1) provided high levels of humoral and cellular immunogenicity against all three subtypes. Moreover, mice immunized with the trivalent AcHERV-based nanovaccine were protected from challenge with HPV 16, 18, and 58 pseudotype viruses. These results suggest that trivalent AcHERV-HPV16/18/58L1 could serve as a potential prophylactic baculoviral nanovaccine against concurrent infection with HPV 16, 18, and 58.     

人乳头瘤病毒16型和11型L1基因双价重组杆状病毒转移质粒的构建及鉴定

目的：构建人乳头瘤病毒16型与11型L1基因双价重组杆状病毒转移质粒并对其进行鉴定。方法：采用：PCR法从尖锐湿疣组织标本中扩增人乳头瘤病毒11型晚期基因L1,并对其进行克隆测序;利用基因重组技术将人乳头瘤病毒16型和11型L1晚期基因共同装入杆状病毒转移载体中,分别位于强启动子Ppolh和弱启动子P10之下;利用酶切和PCR技术对双价重组杆状病毒转移质粒进行鉴定。结果：PCR扩增法获得尖税湿疣组织中感染的人乳头瘤病毒11型的L1基因,得到人乳头瘤病毒16型L1和11型L1基因双价重组杆状病毒转移质粒,经酶切电泳鉴定验证重组成功。结论：本研究成功构建了双价重组杆状病毒转移质粒,为进一步构建双价L1蛋白表达系统进而建立双价基因工程亚单位疫苗打下基础。     

用Bac-to-Bac杆状病毒系统表达人生长激素

利用Bac to Bac杆状病毒载体表达系统将人生长激素 (humangrowthhormone ,hGH)基因cDNA克隆至转移载体pFastBac1中 ,得到pFastBac hGH ,再将其转化进入含穿梭载体Bacmid的受体菌DH10Bac中 ,发生转座作用 ,得到含hGH基因的重组穿梭载体rBacmid hGH .纯化DNA ,直接转染培养的昆虫细胞Sf9,得到重组病毒rAcV Bac hGH .经酶切PCR及Southern杂交鉴定 ,hGH基因正确地插入病毒基因组的多角体蛋白基因启动子下 ,SDS PAGE测得产物蛋白分子量为 2 2kD左右 .用免疫化学发光法测得转染上清中hGH表达水平可达 18μg ml ,与用传统的BEVS表达hGH相比 ,转染上清中hGH表达水平提高 4 0 0倍以上     

Expression of recombinant herpes simplex virus type 2 glycoprotein D by high-density cell culture of <Emphasis Type="Italic">Spodoptera frugiperda</Emphasis>

Herpes simplex virus type 2 (HSV-2) is the major cause of genital herpes in humans. The glycoprotein D of HSV-2 (gD2) is a promising subunit vaccine candidate for the treatment of genital herpes. The aim of the present study was to express a biologically active recombinant gD2 in eukaryotic baculovirus system in quantities sufficient for further studies. Human cDNA encoding a gD2 protein with 393 amino acids was subcloned into the pFastBac HTb vector and the recombinant protein was expressed in Spodoptera frugiperda (Sf9) cells by high-density cell culture. In a stirred bioreactor, the key limiting factors including glucose concentration, glutamine concentration and dissolved oxygen (DO) were optimized for high-density cell growth. The Sf9 cell density could reach 9.6×10⁶ cells/mL and the yield of recombinant gD2 protein was up to 192 mg/L in cell culture under the optimal conditions of 15 mM glucose, 0.4 g/L glutamine and 40% DO. Production of significant amounts of pure, full-length gD2 opened up the possibility to investigate novel functions of gD2. Moreover, the purified recombinant gD2 protein revealed a partial prophylactic immune function in genital herpes of guinea pigs infected with HSV-2.     

Baculovirus titration method based on MOI values for optimizing recombinant protein expression of the anti‐cancer vaccine candidate GA733‐Fc using Sf9 insect cells

The baculovirus expression system has been considered as a highly efficient tool for the production of recombinant biopharmaceutical proteins. The recombinant antigenic glycoprotein GA733 is a cell surface protein that is strongly expressed in human colorectal cancer. Efficient virus titration should be established to achieve optimal multiplicity of infection (MOI) conditions, which are in turn essential for strong expression of the recombinant GA733 fused to the human immunoglobulin IgG Fc fragment (GA733‐Fc) in the baculovirus‐insect system. In the present study, the Sf9 cell line was transfected with plasmid DNA containing the GA733‐Fc expression cassette under the control of the baculovirus polyhedron promoter. MOI values (0.05, 0.1, 0.5, 1, and 3) were calculated based on both microscope observations and results of titration assay and then used to determine the optimum recombinant expression and harvested sample [cell culture media (CM) or cell lysate (CL)]. The pFastBac dual vector carrying the GA733‐Fc gene was constructed to express GA733‐Fc and used to generate recombinant baculoviruses. Western blotting results showed that recombinant protein expression was dependent on the MOI. In addition, CM and CL showed significant differences in protein synthesis and protein secretion capacities. Our findings suggested that our proposed titration method can be used for reliable calculation of MOI values, which significantly influence recombinant GA733‐Fc protein expression in the baculovirus‐insect cell system.     

杆状病毒表达系统的改进及IL-6在昆虫细胞内的表达和纯化

使用同源重组方法,在昆虫细胞内将多角体启动子驱动的EGFP表达盒插入杆状病毒穿梭载体Bacmid的p74位相,经5轮空斑纯化获得重组穿梭载体Bacmid-egfp。然后将Bacmid-egfp转化含转座助手质粒的E.coliDH10B,获得受体菌E.coliDH10Bac-egfp,由于Bacmid-egfp保留了完整的转座结构和α互补功能,因此该菌株和原始E.coliDH10Bac一样能有效的利用各种pFastBac系列的载体进行转座并构建出能指示病毒繁殖和目的基因表达的重组病毒。使用红色荧光蛋白DsRed对系统进行了验证,结果表明重组病毒Bac-egfp-DsRed感染的细胞中绿色荧光蛋白和红色荧光蛋白均得到了高效表达。进一步使用该系统在昆虫细胞中高效表达并纯化了IL-6蛋白,为研究和应用该细胞因子提供物质基础,同时也进一步证明所改造的杆状病毒表达系统的可靠性和实用性。     

利用家蚕杆状病毒表达家蚕肌质网型钙离子ATP酶蛋白

肌质网型钙离子ATP酶(Sacro/endoplasmic reticulum Ca2+-ATPase,Serca)负责将细胞中多余的Ca2+转运并存储于内质网中,从而维持细胞内适宜的Ca2+环境。家蚕Serca创造的细胞内及细胞外Ca2+平衡对家蚕正常生命活动的维持具有重要作用。由于Serca分子量较大并具有10次跨膜结构,很难在大肠杆菌表达系统中表达。为了获得具有生物学活性的重组Serca蛋白,利用p Fast Bac Dual载体构建了用于表达egfp和serca的双元杆状病毒表达载体,转染细胞后获得重组病毒,将重组病毒感染细胞后,成功地在细胞中表达了EGFP和Serca。通过荧光观察及Western blotting分析表明,感染后细胞中Serca和EGFP表达模式一致,从感染后48 h开始表达,在感染后96 h表达量最大。对获得的重组蛋白进行酶活分析,发现感染后48 h至120 h的细胞Serca酶活显著提高。表明具有生物学活性的Serca在此系统中成功获得表达,为深入研究Serca蛋白的功能奠定了基础。